{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:08:24Z","timestamp":1793858904115,"version":"4.6.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Defective \u03b1-galactosidase A (AGAL\/GLA) due to missense or nonsense mutations in the\n                    <jats:italic>GLA<\/jats:italic>\n                    gene results in accumulation of the glycosphingolipids globotriaosylceramide (Gb3) and its deacylated derivate globotriaosylsphingosine (lyso-Gb3) in cells and body fluids. The aberrant glycosphingolipid metabolism leads to a progressive lysosomal storage disorder, i. e. Fabry disease (FD), characterized by chronic inflammation leading to multiorgan damage. Enzyme replacement therapy (ERT) with agalsidase-alfa or -beta is one of the main treatment options facilitating cellular Gb3 clearance. Proteome studies have shown changes in complement proteins during ERT. However, the direct activation of the complement system during FD has not been explored. Here, we demonstrate strong activation of the complement system in 17 classical male FD patients with either missense or nonsense mutations before and after ERT as evidenced by high C3a and C5a serum levels. In contrast to the strong reduction of lyso-Gb3 under ERT, C3a and C5a markedly increased in FD patients with nonsense mutations, most of whom developed anti-drug antibodies (ADA), whereas FD patients with missense mutations, which were ADA-negative, showed heterogenous C3a and C5a serum levels under treatment. In addition to the complement activation, we found increased IL-6, IL-10 and TGF-\u00df1 serum levels in FD patients. This increase was most prominent in patients with missense mutations under ERT, most of whom developed mild nephropathy with decreased estimated glomerular filtration rate. Together, our findings demonstrate strong complement activation in FD independent of ERT therapy, especially in males with nonsense mutations and the development of ADAs. In addition, our data suggest kidney cell-associated production of cytokines, which have a strong potential to drive renal damage. Thus, chronic inflammation as a driver of organ damage in FD seems to proceed despite ERT and may prove useful as a target to cope with progressive organ damage.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2024.1307558","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T23:42:24Z","timestamp":1705534944000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Bj\u00f6rn","family":"Laffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Lenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Ehlers-Jeske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"K\u00f6hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry's disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"B2","article-title":"Fabry disease: clinical features and recent advances in enzyme replacement therapy","volume":"31","author":"Desnick","year":"2001","journal-title":"Adv Nephrol Necker Hosp"},{"key":"B3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1651-2227.2007.00198.x","article-title":"Structure-function relationships in alpha-galactosidase A","volume":"96","author":"Garman","year":"2007","journal-title":"Acta Paediatr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11940-016-0414-5","article-title":"Fabry disease: recognition, diagnosis, and treatment of neurological features","volume":"18","author":"Ranieri","year":"2016","journal-title":"Curr Treat Options Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20763","article-title":"A meta-analysis of nonsense mutations causing human genetic disease","volume":"29","author":"Mort","year":"2008","journal-title":"Hum Mutat"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/BF00484919","article-title":"Residual activity of alpha-galactosidase A in Fabry's disease","volume":"13","author":"Romeo","year":"1975","journal-title":"Biochem Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"Yam","year":"2005","journal-title":"FASEB J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01486-1","article-title":"Fabry disease: the current treatment landscape","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018030329","article-title":"Effects of enzyme replacement therapy and antidrug antibodies in patients with fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide","volume":"109","author":"De Francesco","year":"2013","journal-title":"Mol Genet Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-021-02058-z","article-title":"Pathology and pathogenic pathways in fabry nephropathy","volume":"25","author":"Feriozzi","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111339","article-title":"alpha-galactosidase a deficiency in fabry disease leads to extensive dysregulated cellular signaling pathways in human podocytes","volume":"22","author":"Jehn","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol Genet Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in fabry disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature21368","article-title":"Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease","volume":"543","author":"Pandey","year":"2017","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2009.10.178","article-title":"A validated disease severity scoring system for Fabry disease","volume":"99","author":"Giannini","year":"2010","journal-title":"Mol Genet Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin Genet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.jaci.2017.12.1001","article-title":"Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion","volume":"141","author":"Lenders","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12882-018-1126-8","article-title":"Glomerular filtration rate: new age- and gender- specific reference ranges and thresholds for living kidney donation","volume":"19","author":"Fenton","year":"2018","journal-title":"BMC Nephrol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02664","article-title":"Age and sex-associated changes of complement activity and complement levels in a healthy caucasian population","volume":"9","author":"Gaya Da Costa","year":"2018","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2017-104704","article-title":"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy","volume":"54","author":"Heo","year":"2017","journal-title":"J Med Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.04.027","article-title":"The role of the anaphylatoxins in health and disease","volume":"46","author":"Klos","year":"2009","journal-title":"Mol Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1038\/s41598-022-10936-z","article-title":"Brief report on the relation between complement C3a and anti dsDNA antibody in systemic lupus erythematosus","volume":"12","author":"Cai","year":"2022","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew196","article-title":"Autoantibodies against a complement component 1 q subcomponent contribute to complement activation and recurrent thrombosis\/pregnancy morbidity in anti-phospholipid syndrome","volume":"55","author":"Oku","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/cei.13498","article-title":"The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis","volume":"202","author":"Moiseev","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013030290","article-title":"Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy","volume":"25","author":"Debiec","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2020.11.032","article-title":"Lupus nephritis with obvious igA deposits in the kidneys","volume":"363","author":"Li","year":"2022","journal-title":"Am J Med Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00816-y","article-title":"Glomerulonephritis: immunopathogenesis and immunotherapy","volume":"23","author":"Anders","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"101331","DOI":"10.1016\/j.smim.2019.101331","article-title":"Complement dysregulation in glomerulonephritis","volume":"45","author":"Kaartinen","year":"2019","journal-title":"Semin Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26854","article-title":"Complement-driven hemolytic uremic syndrome","author":"Leon","year":"2023","journal-title":"Am J Hematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13747","article-title":"Systemic complement activation in anti-neutrophil cytoplasmic antibody-associated vasculitis and necrotizing glomerulonephritis","volume":"26","author":"Bantis","year":"2021","journal-title":"Nephrol (Carlton)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40261-023-01298-z","article-title":"Avacopan, a novel competitive C5a receptor antagonist, for severe antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"43","author":"Nguyen","year":"2023","journal-title":"Clin Drug Investig"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00404.2021","article-title":"Folic acid-mediated fibrosis is driven by C5a receptor 1-mediated activation of kidney myeloid cells","volume":"322","author":"Sahu","year":"2022","journal-title":"Am J Physiol Renal Physiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00752-7","article-title":"Role of perivascular cells in kidney homeostasis, inflammation, repair and fibrosis","volume":"19","author":"Tanaka","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.11.008","article-title":"Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment","volume":"126","author":"Van Der Veen","year":"2019","journal-title":"Mol Genet Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2862","article-title":"Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1","volume":"18","author":"Karsten","year":"2012","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01544-8","article-title":"Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy","volume":"24","author":"Nimmerjahn","year":"2023","journal-title":"Nat Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01910215","article-title":"Drug-induced glomerular disease: immune-mediated injury","volume":"10","author":"Hogan","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042617-053245","article-title":"Complement and the regulation of T cell responses","volume":"36","author":"West","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s40292-020-00414-w","article-title":"The role of immunity in fabry disease and hypertension: A review of a novel common pathway","volume":"27","author":"Del Pinto","year":"2020","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v3.i4.91","article-title":"Role of IL-10 in the progression of kidney disease","volume":"3","author":"Sinuani","year":"2013","journal-title":"World J Transplant"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00365.2015","article-title":"TGF-beta signaling in the kidney: profibrotic and protective effects","volume":"310","author":"Sureshbabu","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00405","article-title":"Interleukin-6 signaling pathway and its role in kidney disease: an update","volume":"8","author":"Su","year":"2017","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2019.10.010","article-title":"Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis","volume":"129","author":"Rozenfeld","year":"2020","journal-title":"Mol Genet Metab"},{"key":"B55","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12882-017-0509-6","article-title":"Higher plasma transforming growth factor (TGF)-beta is associated with kidney disease in older community dwelling adults","volume":"18","author":"Mehta","year":"2017","journal-title":"BMC Nephrol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.smim.2018.02.006","article-title":"An unexpected player in Gaucher disease: The multiple roles of complement in disease development","volume":"37","author":"Pandey","year":"2018","journal-title":"Semin Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molimm.2005.06.028","article-title":"Complement and Toll-like receptors: key regulators of adaptive immune responses","volume":"43","author":"Hawlisch","year":"2006","journal-title":"Mol Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0168-x","article-title":"New insights into the immune functions of complement","volume":"19","author":"Reis","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1096\/fj.13-242693","article-title":"Sublytic C5b-9 induces IL-6 and TGF-beta1 production by glomerular mesangial cells in rat Thy-1 nephritis through p300-mediated C\/EBPbeta acetylation","volume":"28","author":"Zhang","year":"2014","journal-title":"FASEB J"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"Roth","year":"2021","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1307558\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T23:42:26Z","timestamp":1705534946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1307558\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2024.1307558"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1307558","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"article-number":"1307558"}}